Skip to main content
The British Journal of Cancer. Supplement logoLink to The British Journal of Cancer. Supplement
. 1990 Jul;10:34–36.

Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow-up of colorectal cancer and other tumours producing CEA.

A Hertel 1, R P Baum 1, M Lorenz 1, T Baew-Christow 1, A Encke 1, G Hör 1
PMCID: PMC2149521  PMID: 2166552

Abstract

Using the intact monoclonal IgG1 anti-CEA antibody BW 431/26 (Behringwerke Marburg, FRG) labelled with 99mTc by a new labelling procedure (Schwarz method), 72 patients suspected of tumour recurrences (colorectal cancer, n = 59) and with rising serum carcinoembryonic antigen (CEA) levels were studied. Sixty-nine of 72 studies had a positive result by immunoscintigraphy of which 52 have since been proven histologically/clinically. In six patients only immunoscintigraphy revealed a tumour recurrence while all other diagnostic modalities were negative. Of 52 studies 46 were true positive (diagnostic sensitivity 88%). In this series there was one false positive result. About one-third of all patients injected with the antibody developed a human anti-mouse response (HAMA), but no severe side effects were seen even after four applications. For the follow-up of colorectal and other CEA positive adenocarcinomas this 99mTc-labelled monoclonal antibody seems to be very promising in patients with rising serum CEA, especially if conventional diagnostic imaging procedures remain negative.

Full text

PDF

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baum R. P., Hertel A., Lorenz M., Schwarz A., Encke A., Hör G. 99Tcm-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results. Nucl Med Commun. 1989 May;10(5):345–352. doi: 10.1097/00006231-198905000-00005. [DOI] [PubMed] [Google Scholar]
  2. Bosslet K., Steinsträsser A., Schwarz A., Harthus H. P., Lüben G., Kuhlmann L., Sedlacek H. H. Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas. Eur J Nucl Med. 1988;14(11):523–528. doi: 10.1007/BF00286769. [DOI] [PubMed] [Google Scholar]
  3. Schroff R. W., Foon K. A., Beatty S. M., Oldham R. K., Morgan A. C., Jr Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 1985 Feb;45(2):879–885. [PubMed] [Google Scholar]

Articles from The British Journal of Cancer. Supplement are provided here courtesy of Cancer Research UK

RESOURCES